Lonza Group AG (LZAGY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Lonza Group AG (LZAGY) Healthcare & Pipeline Overview

Lonza Group AG is a leading global CDMO providing integrated solutions across the pharmaceutical, biotech, and nutrition industries, distinguished by its broad service portfolio, technological innovation in cell and gene therapy, and established presence in key global markets, positioning it as a critical partner for drug developers.

What Is the Investment Thesis for LZAGY?

Lonza Group AG presents a notable research candidate driven by the increasing demand for outsourced pharmaceutical development and manufacturing services. The company's diverse service portfolio, spanning biologics, small molecules, cell and gene therapies, and capsules & health ingredients, positions it to capitalize on multiple growth avenues within the healthcare sector. Lonza's established presence in key global markets and its focus on innovation, particularly in cell and gene therapy, provide a competitive edge. With a P/E ratio of 37.70 and a profit margin of 13.9%, the company demonstrates financial stability. Upcoming catalysts include continued expansion in the cell and gene therapy market and strategic partnerships to enhance its service offerings. Potential risks include increased competition in the CDMO space and regulatory challenges associated with novel therapies.

Based on FMP financials and quantitative analysis

LZAGY Key Highlights

• Market capitalization of $49.3B reflects Lonza's significant presence in the healthcare sector.
• P/E ratio of 37.70 indicates investor confidence in the company's earnings potential.
• Profit margin of 13.9% demonstrates Lonza's ability to generate profits from its operations.
• Gross margin of 34.6% highlights the efficiency of Lonza's manufacturing processes and pricing strategies.
• Dividend yield of 0.82% provides a steady income stream for investors.

Who Are LZAGY's Competitors?

LZAGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LZAGY's Key Strengths?

• Diverse service portfolio across biologics, small molecules, and cell and gene therapies.
• Global presence and established relationships with key customers.
• Strong reputation for quality and reliability.
• Focus on innovation and advanced technologies.

What Are LZAGY's Weaknesses?

• High capital expenditures required for manufacturing infrastructure.
• Exposure to regulatory risks and compliance requirements.
• Dependence on key customers and contracts.
• Potential for supply chain disruptions.

What Could Drive LZAGY Stock Higher?

• Continued expansion in the cell and gene therapy market, driven by increasing demand for personalized medicine.
• Strategic partnerships and collaborations to enhance service offerings and expand market reach.
• Potential regulatory approvals for novel therapies and drug products manufactured by Lonza.
• Increased outsourcing of pharmaceutical manufacturing by pharmaceutical and biotech companies.

What Are the Key Risks for LZAGY?

• Negative return on equity (-3.1%) — the business is not currently generating profit on shareholder capital.
• Increased competition in the CDMO space, leading to pricing pressures and reduced market share.
• Regulatory challenges and compliance requirements associated with novel therapies and drug products.
• Economic downturns that could reduce demand for pharmaceutical products and services.
• Currency risk associated with fluctuations in the exchange rate between the U.S. dollar and the Swiss franc.
• Risks associated with operating in multiple countries, including political instability and regulatory changes.

What Are the Growth Opportunities for LZAGY?

• Expansion in Cell and Gene Therapy: The cell and gene therapy market is experiencing rapid growth, driven by breakthroughs in personalized medicine and the potential to treat previously incurable diseases. Lonza's Cell & Gene segment is well-positioned to capitalize on this trend, offering contract development and manufacturing services for a range of cell therapies, gene therapies, and exosome-based therapies. The global cell and gene therapy market is projected to reach $55.76 billion by 2027, growing at a CAGR of 33.9% from 2020. Lonza's investment in advanced technologies and platforms for cell and gene therapy manufacturing provides a competitive advantage in this high-growth market.
• Strategic Partnerships and Collaborations: Lonza can drive growth by forming strategic partnerships and collaborations with pharmaceutical and biotech companies. These partnerships can provide access to new technologies, expand its service offerings, and secure long-term contracts. For example, collaborating with a company specializing in drug delivery technologies could enhance Lonza's capabilities in developing and manufacturing complex drug products. These collaborations would enable Lonza to offer more comprehensive solutions to its customers and strengthen its position as a preferred CDMO partner. The timeline for realizing the benefits of these partnerships would depend on the specific agreements and the time required to integrate new technologies and services.
• Geographic Expansion in Emerging Markets: Expanding its presence in emerging markets, such as Asia and Latin America, presents a significant growth opportunity for Lonza. These regions are experiencing increasing demand for pharmaceutical products and services, driven by growing populations, rising healthcare expenditures, and improving access to healthcare. Establishing manufacturing facilities and expanding its sales and marketing efforts in these markets would enable Lonza to tap into new customer bases and diversify its revenue streams. The timeline for geographic expansion would depend on regulatory approvals, infrastructure development, and market entry strategies.
• Increased Outsourcing of Pharmaceutical Manufacturing: The trend of pharmaceutical companies outsourcing their manufacturing activities is expected to continue, driven by the desire to reduce costs, improve efficiency, and focus on core competencies. Lonza is well-positioned to benefit from this trend, offering a comprehensive range of manufacturing services for both biologics and small molecules. By providing high-quality manufacturing services at competitive prices, Lonza can attract new customers and expand its market share. The timeline for realizing the benefits of increased outsourcing would depend on the overall growth of the pharmaceutical industry and the adoption of outsourcing strategies by pharmaceutical companies.
• Development of Innovative Dosage Form Solutions: Lonza's Capsules & Health Ingredients segment can drive growth by developing innovative dosage form solutions that improve drug delivery and patient compliance. This includes developing capsules with enhanced bioavailability, controlled-release properties, and targeted delivery mechanisms. By offering these innovative solutions, Lonza can differentiate itself from competitors and attract customers seeking advanced drug delivery technologies. The global drug delivery market is projected to reach $243.7 billion by 2027, growing at a CAGR of 7.8% from 2020. Lonza's focus on innovation in dosage form solutions positions it to capitalize on this growing market.

What Opportunities Does LZAGY Have?

• Expansion in emerging markets.
• Increased outsourcing of pharmaceutical manufacturing.
• Development of innovative dosage form solutions.
• Strategic partnerships and collaborations.

What Threats Does LZAGY Face?

• Increased competition in the CDMO space.
• Pricing pressures from pharmaceutical companies.
• Technological advancements that could disrupt the industry.
• Economic downturns that could reduce demand for pharmaceutical products.

What Are LZAGY's Competitive Advantages?

• Extensive manufacturing capabilities and infrastructure.
• Strong reputation for quality and reliability.
• Deep expertise in biologics, small molecules, and cell and gene therapies.
• Long-standing relationships with key customers.
• Global presence and reach.

What Does LZAGY Do?

Founded in 1897 in Switzerland, Lonza began as an energy company before transitioning into chemical production and eventually specializing in life sciences. Today, Lonza Group AG stands as a prominent contract development and manufacturing organization (CDMO), offering a comprehensive suite of services across the pharmaceutical, biotech, and nutrition sectors. The company operates through four key segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. The Biologics segment focuses on the development and manufacturing of biopharmaceuticals, supporting clinical and commercial manufacturing needs throughout the entire product lifecycle. The Small Molecules segment provides integrated services for small molecule drug substances, from design and development to manufacturing. The Cell & Gene segment is dedicated to advancing technologies and platforms for cell and gene therapies, offering contract development, manufacturing services, and regulatory support. The Capsules & Health Ingredients segment provides capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. With a global presence spanning Europe, North America, Latin America, Asia, and Australia, Lonza serves a diverse clientele, ranging from emerging biotech firms to established pharmaceutical giants. Its commitment to innovation and quality has solidified its position as a trusted partner in the healthcare industry.

What Products and Services Does LZAGY Offer?

• Contract development and manufacturing of biopharmaceuticals.
• Integrated development and manufacturing services for small molecule drug substances.
• Development of technologies and platforms for cell and gene therapies.
• Contract development and manufacturing services for cell and gene therapies.
• Regulatory support for cell and gene therapies.
• Supply of specialty raw materials and enabling technology solutions.
• Offer capsules, dosage form solutions, and health ingredients.
• Serve pharmaceutical and nutraceutical customers.

How Does LZAGY Make Money?

• Fee-for-service model for contract development and manufacturing services.
• Sales of capsules, dosage form solutions, and health ingredients.
• Licensing of technologies and platforms.
• Strategic partnerships and collaborations.

What Industry Does LZAGY Operate In?

Lonza operates within the rapidly growing contract development and manufacturing organization (CDMO) industry. The increasing complexity of drug development, coupled with the rising demand for specialized manufacturing capabilities, is driving growth in this sector. The global CDMO market is projected to reach $225.27 billion by 2028, growing at a CAGR of 8.5% from 2021. Lonza competes with other major CDMOs, such as ARGNF (argenx SE), CHALF (Charles River Laboratories International, Inc.), and DSNKY (Daiichi Sankyo Company, Limited). Lonza's broad service portfolio and focus on innovation position it as a key player in this competitive landscape.

Who Are LZAGY's Key Customers?

• Pharmaceutical companies.
• Biotech companies.
• Nutraceutical companies.
• Research institutions.

F-Score 7/9Financial Health

Lonza Group AG's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.55 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -3%Key Financial Metrics

Return on equity for Lonza Group AG stands at -3.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.7%, the inverse of the P/E and a quick read on earnings relative to price.

Lonza Group AG (LZAGY) Valuation Context

Valued at $49.3B, LZAGY is classified as a large-cap stock. Relative to its peer group, LZAGY's quantitative score of 44/100 is below the peer average of 62/100.

FY2026 estForward Outlook

Wall Street analysts project Lonza Group AG revenue of about $7.06B for fiscal 2026, with EPS near $1.75. The estimate reflects 12 contributing analysts.

LZAGY Financials

LZAGY Latest News

LZAGY Analyst Consensus

LZAGY MoonshotScore

What Investors Ask About Lonza Group AG (LZAGY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources